In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats
- 1 November 2001
- journal article
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 62 (11) , 1755-1760
- https://doi.org/10.2460/ajvr.2001.62.1755
Abstract
Objective—To determine potency and selectivity of nonsteroidal anti-inflammatory drugs (NSAID) and cyclooxygenase- (COX-) specific inhibitors in whole blood from horses, dogs, and cats.Sample Population—Blood samples from 30 healthy horses, 48 healthy dogs, and 9 healthy cats.Procedure—Activities of COX-1 and COX-2 were determined by measuring coagulation-induced thromboxane B2and lipopolysaccharide-induced prostaglandin E2concentrations, respectively, in whole blood with and without the addition of various concentrations of phenylbutazone, flunixin meglumine, ketoprofen, diclofenac, indomethacin, meloxicam, carprofen, 5-bromo-2[4-fluorophenyl]-3-[4- methylsulfonylphenyl]-thiophene (DuP 697), 5,5- dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furan one (DFU), 3-(3,4-difluorophenyl)- 4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone (MF-tricyclic), and celecoxib. Potency of each test compound was determined by calculating the concentration that resulted in inhibition of 50% of COX activity (IC50). Selectivity was determined by calculating the ratio of IC50for COX-1 to IC50 for COX-2 (COX-1/COX-2 ratio).Results—The novel compound DFU was the most selective COX-2 inhibitor in equine, canine, and feline blood; COX-1/COX-2 ratios were 77.5, 74, and 69, respectively. Carprofen was the weakest inhibitor of COX-2, compared with the other COX-2 selective inhibitors, and did not inhibit COX-2 activity in equine blood. In contrast, NSAID such as phenylbutazone and flunixin meglumine were more potent inhibitors of COX-1 than COX-2 in canine and equine blood.Conclusions and Clinical Relevance—The novel COX-2 inhibitor DFU was more potent and selective in canine, equine, and feline blood, compared with phenylbutazone, flunixin meglumine, and carprofen. Compounds that specifically inhibit COX-2 may result in a lower incidence of adverse effects, compared with NSAID, when administered at therapeutic dosages to horses, dogs, and cats. (Am J Vet Res2001;62:1755–1760)Keywords
This publication has 23 references indexed in Scilit:
- Cyclooxygenase knockout miceBiochemical Pharmacology, 1999
- Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2Rheumatology, 1999
- Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitorBritish Journal of Pharmacology, 1997
- MeloxicamDrugs, 1996
- Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulcerationCell, 1995
- Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouseCell, 1995
- Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase IINature, 1995
- Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDS and Cox 2 inhibitorsInflammation Research, 1995
- Gastrointestinal Damage Associated with the Use of Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1992
- Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.Proceedings of the National Academy of Sciences, 1975